Plains Resources News

Protalix BioTherapeutics, Inc. today announced the appointment of Sandra Lauterbach to Vice President, Sales and Commercial Affairs.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Protalix Biotherapeutics, Inc. has announced the completion of its New Drug Application submission with the U.S. Food and Drug Administration for taliglucerase alfa, a plant-cell expressed form of glucocerebrosidase for the potential treatment of Gaucher's disease.

KIRKLAND, Wash.-- --Clearwire Communications, LLC, an operating subsidiary of Clearwire Corporation announced today the expansion of its sales operations for CLEAR's... FAIRFIELD, N.J.-- --Kyocera Mita America, Inc., one of the world's leading document solutions companies, announced today that its TASKalfa 500ci color multifunctional product ...

Pfizer will spend up to $115 million for rights to an Israeli biotech company's experimental drug and its promising technology for making that drug and others in carrot cells.

Del Mar, CA - Mundus Group, Inc. recently announced that subsidiary Airstar International and Aero Deportes entered into an Exclusive Dealer Agreement together.

As Shire plc gears up for an early 2010 PDUFA date for its enzyme replacement therapy velaglucerase alfa in Gaucher's disease, potential competitor Protalix BioTherapeutics Inc.

Pfizer Inc. is wooing up-and-coming Israeli biotech Protalix Biotherapeutics for a possible buyout or partnership, the financial newspaper TheMarker reported Monday.

Pfizer , the world's largest drugmaker with R&D operations in Connecticut, is considering a cooperation deal with Protalix Biotherapeutics , and may even try to buy the Israeli company, Reuters said, citing a published report.

This morning RadioShack posted net income for the third quarter of $37.4 million, or $0.30 per diluted share, which was below Wall Street estimate.

The report also includes recent company news updates. Competitor Reports provide detailed analysis of a companyA's products by therapeutic indication, a summary of its overall pipeline as well as insight into the predicted likelihood of clinical success for each pipeline product.

Drug stocks edged up in early trading Monday as shares of BioCryst Pharmaceuticals soared on news that U.S. regulators will allow its experimental flu treatment peramivir to be given to hospitalized H1N1 flu victims under certain circumstances.

Zacks Analyst Blog Highlights: US Bancorp, Visa Inc., Genzyme Corp, Shire plc and Protalix BioTherapeutics Inc.

Protalix BioTherapeutics announced positive top -line results from its phase three clinical trial of its treatment for Gaucher disease.

Shares of the following companies made notable moves in the stock market on Thursday: Gainers DeVry Inc.

On 10/15/09, Protalix BioTherapeutics announced positive top-line results of a pivotal Phase 3 study of its lead drug candidate, UPLYSO in treatment nave patients diagnosed with Gaucher disease.

Protalix BioTherapeutics Inc. reported positive Phase III data for its enzyme replacement therapy Uplyso , staking its claim as another serious contender in the Gaucher disease space held almost exclusively by Genzyme Corp.'s Cerezyme .

Protalix BioTherapeutics, Inc. , announced today positive top-line results from the Company's pivotal Phase III clinical trial of UPLYSO in treatment naive patients diagnosed with Gaucher disease.

Protalix Biotherapeutics, Inc. , reported preclinical data on pr-antiTNF, a biosimilar version of etanercept .

Protalix BioTherapeutics, Inc. gained orphan drug status from the US FDA for prGCD, a development drug for Gaucher's disease, on September 9. The orphan drug designation for prGCD was granted by the FDA's Office of Orphan Products Development and comes less than a month after the drug received fast-track designation from the FDA.